Durvalumab Receives FDA Approval for Use in Unresectable NSCLC

Durvalumab Receives FDA Approval for Use in Unresectable NSCLC
The FDA has approved the use of durvalumab (Imfinzi, AstraZeneca) for treatment of stage III unresectable non-small cell lung cancer (NSCLC) where the cancer has not progressed after chemotherapy and radiation. This marks the first immunotherapy trea...

Nivolumab Plus Chemoradiation Shown to Be Safe in Head and Neck Cancers

Nivolumab Plus Chemoradiation Shown to Be Safe in Head and Neck Cancers
Results of the RTOG Foundation 3504 trial showed that nivolumab immunotherapy combined with radiation therapy and either weekly (40 mg/m 2 ) or high-dose (100 mg/m 2 every 3 weeks) cisplatin was safe for patients with newly-diagnosed local-regionally...

Best Practices in Thyroid Cancer Management

Best Practices in Thyroid Cancer Management
Thyroid cancer is one of the most prevalent cancers in the United States. An estimated 56,870 new cases are diagnosed annually, and 2,010 people die of the disease. Thyroid cancer is typically more aggressive in men than women and becomes increasingl...

FDA Approves Apalutamide in Non-Metastatic Castration-Resistant Prostate Cancer

FDA Approves Apalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
Apalutamide (Erleada, Janssen Biotech, Inc.) has received approval for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). This is the first FDA-approved treatment in this setting. Approval was based on findi...

Metastatic Castration-Resistant Prostate Cancer: An Interview with Tanya Dorff, MD

Metastatic Castration-Resistant Prostate Cancer: An Interview with Tanya Dorff, MD
Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to an...

FDA Expands Use of Abiraterone for High-Risk Prostate Cancer

FDA Expands Use of Abiraterone for High-Risk Prostate Cancer
The FDA has approved the use of abiraterone acetate (Zytiga, Janssen Biotech) plus prednisone for the treatment of patients with newly diagnosed, metastatic high-risk castration-sensitive prostate cancer. This cancer type accounts for approximately 3...

Veno-Occlusive Disease: An Interview with Phyllis McKiernan, APN, MSN, OCN® and Michelle N. Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON

Veno-Occlusive Disease: An Interview with Phyllis McKiernan, APN, MSN, OCN® and Michelle N. Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON
Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome, is a potentially life-threatening complication of hematopoietic stem cell transplant (HSCT), characterized by weight gain, fluid retention with ascites, tender hepatomegaly,...

Lutetium Lu 177 Dotatate Approved for GEP-NETS

Lutetium Lu 177 Dotatate Approved for GEP-NETS
The FDA approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc.) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, ...

Diagnostic Assay Now Approved for all Myeloproliferative Neoplams

Diagnostic Assay Now Approved for all Myeloproliferative Neoplams
The Ipsogen JAK2 RGQ PCR kit (Qiagen) has received additional FDA approval for the diagnosis of all myeloproliferative neoplasms (MPNs). These hematologic malignancies prevent blood cells in bone marrow from growing into healthy, mature cells. Last y...

Johns Hopkins Develops Noninvasive Blood Test for 8 Common Cancers

Johns Hopkins Develops Noninvasive Blood Test for 8 Common Cancers
Johns Hopkins Kimmel Cancer Center has developed a single, noninvasive blood test called CancerSEEK to screen for 8 types of common cancer. These include cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, and breast, which a...

Safety Alert Issued for Antiemetic Agent Rolapitant

Safety Alert Issued for Antiemetic Agent Rolapitant
​A safety alert has been issued for rolapitant (Varubi, TESARO, Inc.), which is approved in adults in combination with other agents that prevent nausea and vomiting associated with cancer chemotherapy. Anaphylaxis, anaphylactic shock, and other ...

Olaparib Approved for HER2-Negative Metastatic Breast Cancer

Olaparib Approved for HER2-Negative Metastatic Breast Cancer
Today the FDA granted regular approval to the PARP inhibitor olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic br...

FDA Broadens Indication for Afatinib in Lung Cancer

FDA Broadens Indication for Afatinib in Lung Cancer
Today the FDA approved afatinib (Gilotrif, Boehringer Ingelheim Pharmaceutical, Inc.) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epiderma...

FDA Expands Use of Denosumab in Myeloma Patients

FDA Expands Use of Denosumab in Myeloma Patients
Today the FDA approved denosumab (XGEVA, Amgen) for the treatment of skeletal-related events in patients with multiple myeloma. Of the 114,000 new cases of multiple myeloma diagnosed worldwide annually, approximately 90% experience osteolytic lesions...

What do you consider "sorafenib failure?" Progression on radiological evaluation, clinical evaluation, or both?

What do you consider "sorafenib failure?" Progression on radiological evaluation, clinical evaluation, or both?
Thomas A. Abrams, MD: Clinical deterioration that is not related to obvious AEs of sorafenib has to be regarded as a progression or sorafenib failure, especially if there's corroborating evidence such as biochemical worsening, AFPs going up, worsenin...